课题基金 / 基金详情

项目摘要

项目成果

Thomas Cooper Woods的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项建议代表了我们实验室正在进行的努力的第二阶段,目的是阐明糖尿病患者血管疾病发生率增加背后的机制。我们的研究重点是使用雷帕霉素(西罗莫斯)洗脱支架预防支架内再狭窄、球囊血管成形术后动脉再狭窄以及支架植入,因为大规模的临床试验表明,这种治疗方法在糖尿病人群中的有效性降低。这项工作的第一阶段已经确定胰岛素抵抗在这种疗效丧失中起着重要作用,并表明胰岛素刺激胰岛素受体途径以外的途径(非同源途径)的能力起到了作用。目前的研究旨在确定胰岛素在改变血管系统对雷帕霉素治疗的反应中的作用。虽然我们专注于动脉再狭窄,但这些研究对所有血管增生性疾病(如动脉粥样硬化)的治疗都有意义,因为我们正在研究糖尿病的存在如何改变动脉对多种刺激的反应的分子机制。 假设:在胰岛素抵抗的情况下,胰岛素更强烈地刺激IGFR通路,使ERK和Akt活性之间的平衡向ERK转移,并降低靶向mTOR通路预防支架内再狭窄的效果。 支架内再狭窄的进展过程与动脉粥样硬化相似,但大大加快,这一过程由Russell Ross的血管损伤反应模型描述。简而言之,动脉的初始损伤(例如球囊血管成形术)会导致内皮功能障碍和炎症反应。这种炎症反应促使血管平滑肌细胞(VSMC)向内膜迁移和增殖,形成新的内膜,导致管腔丢失和动脉重塑。雷帕霉素通过抑制血管对损伤反应的VSMC增殖和迁移成分而阻止再狭窄。这项建议的策略是研究胰岛素对雷帕霉素在正常、胰岛素抵抗和2型糖尿病条件下调节血管损伤反应能力的影响。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This proposal represents the second stage of the ongoing efforts in our laboratory to elucidate the mechanisms behind the increased rate of vascular diseases in patients with Diabetes Mellitius. We have focused our research on the use of rapamycin (sirolimus) eluting stents for the prevention of in-stent restenosis, the re-narrowing of an artery following balloon angioplasty coupled with the stent implantatin, as large scale clinical trials have demonstrated that the efficacy of this treatment is reduced in the diabetic population. The first stage of this effort has identified that insulin resistance plays an important role in this loss of efficacy and suggested a role for insulin's ability to stimulate pathways other than the insulin receptor pathway (non-cognate). The present studies are directed at determining insulin's role in altering the response of the vasculature to treatment with rapamycin. While we are focused on the in-stet restenosis, these studies have implications for the treatment of all vasculoproliferative diseases (e.g. atherosclerosis) as we are examining how the presence of diabetes alters the molecular mechanisms underlying arterial response to multiple stimuli. Hypothesis: Under insulin resistant conditions insulin stimulates the IGFR pathway more robustly shifting the balance between ERK and Akt activity towards ERK and diminishing the efficacy of targeting the mTOR pathway to prevent in-stent restenosis. The process by which in-stent restenosis proceeds in similar albeit greatly accelerated, to that fo atherosclerosis and is descrived by the vascular response to injury model of Russell Ross. In short, an initial injury to the arter (e.g. balloon angioplasty) leads to endothelial dysfunction and an inlammatory response. THis inflammatory response drives vascular smooth muscle cell (VSMC) migration to the intima and proliferation to form a neointima, resulting in lumen loss and arterial remodeling. Rapamycin blocks restenosis through inhibition of the VSMC proliferatino and migration component of the vascular response to injury. The strategy of this proposal is to examine the effects of insulin on rapamycin's ability to regulate the vascular response to injury under normal, insulin resistant, and type 2 diabetic conditions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of VSMC-Derived Exosomes in the Cardiovascular Complications of Diabetes
  • 批准号:
    9251878
  • 项目类别:
  • 资助金额:
    $37.74万
  • 财政年份:
    2016
  • 负责人:
    Thomas Cooper Woods
  • 依托单位:
P9: REGULATION OF VSMC FUNCTION BY THE INSULIN SIGNALING PATHWAY
  • 批准号:
    8168191
  • 项目类别:
  • 资助金额:
    $26.56万
  • 财政年份:
    2010
  • 负责人:
    Thomas Cooper Woods
  • 依托单位:
P9: REGULATION OF VSMC FUNCTION BY THE INSULIN SIGNALING PATHWAY
  • 批准号:
    7959749
  • 项目类别:
  • 资助金额:
    $20.22万
  • 财政年份:
    2009
  • 负责人:
    Thomas Cooper Woods
  • 依托单位:
海外基金